Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study cohort | All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| percutaneous coronary intervention | Device | percutaneous coronary angioplasty with implantation of at least one Biomime stent |
|
| Measure | Description | Time Frame |
|---|---|---|
| target vessel revascularization | rate of target vessel percutaneous or surgical reintervention for recurrent symptoms or inducible ischemia at follow up testes | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| death from any cause | death from any cause after the procedure | 1 year |
| cardiac death | death form cardiac causes (reinfarction, sudden cardiac death, death during coronary reintervention, heart failure, arrhythmias) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All comers patients with coronary artery disease treated with percutaneous coronary intervention and a Biomime stent, age > 18 years
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alessandro Lupi, MD | Contact | +3903213733236 | lupialessandro1@tin.it |
| Name | Affiliation | Role |
|---|---|---|
| Alessandro Lupi, MD | Azienda Ospedaliero Universitaria Maggiore della Carita | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Azienda Ospedaliero Universitaria Maggiore della Carita | Recruiting | Novara | Piedmont | 28100 | Italy |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D062645 | Percutaneous Coronary Intervention |
| ID | Term |
|---|---|
| D057510 | Endovascular Procedures |
| D014656 | Vascular Surgical Procedures |
| D013504 | Cardiovascular Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| reinfarction | reinfarction in the myocardial region supplied by the treated coronary artery | 1 year |
| target lesion revascularization | rate of target lesion percutaneous reintervention for recurrent symptoms or inducible ischemia at follow up testes | 1 year |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D019060 | Minimally Invasive Surgical Procedures |